Showing results (231-240 of 981) with videos related to
Sort By:
Pageof 99
Cardiovascular Therapeutics|July 8, 2022
Effectiveness and Safety of Nonvitamin K Oral Anticoagulants Rivaroxaban and Apixaban in Patients with Venous Thromboembolism: A Meta-Analysis of Real-World StudiesOlivia Wu, Stephen Morris, Torben Bjerregaard Larsen, et al.Cardiovascular Therapeutics|July 11, 2022
Heme Oxygenase 1/Peroxisome Proliferator-Activated Receptor Gamma Pathway Protects Intimal Hyperplasia and Mitigates Arteriovenous Fistula Dysfunction by Regulating Oxidative Stress and Inflammatory ResponseTingfei Xie, Yunpeng Xu, Lecai Ji, et al.Cardiovascular Therapeutics|May 25, 2010
Therapeutic strategies in patients with chronic stable coronary artery diseaseMichael J Zellweger, Matthias E PfistererCardiovascular Therapeutics|October 27, 2010
Erythropoiesis-stimulating agents and heart failureErik Lipšic, Peter van der Meer, Dirk J van VeldhuisenCardiovascular Therapeutics|October 16, 2010
The potential for clinical use of cannabinoids in treatment of cardiovascular diseasesRonen Durst, Chaim LotanCardiovascular Therapeutics|October 16, 2010
MicroRNA-based therapeutic approaches in the cardiovascular systemJ Fiedler, S K Gupta, T ThumCardiovascular Therapeutics|July 15, 2010
The antianginal agent ranolazine is a potent antiarrhythmic agent that reduces ventricular arrhythmias: through a mechanism favoring inhibition of late sodium channelRobert A Kloner, Joan S Dow, Anil BhandariCardiovascular Therapeutics|July 15, 2010
Aerobic exercise prescription in adult heart transplant recipients: a reviewVitor Oliveira Carvalho, Edimar Alcides Bocchi, Guilherme Veiga GuimarãesCardiovascular Therapeutics|July 22, 2010
New antithrombotics for atrial fibrillationLuke R E Bereznicki, Gregory M PetersonCardiovascular Therapeutics|December 1, 2010
Vascular closure devices in acute coronary syndromes: from arbitrary to a necessity?Jamil B Dihu, Amar R Chadaga, Timothy A SanbornPageof 99